40th week of 2013 patent applcation highlights part 62 |
Patent application number | Title | Published |
20130261071 | EXOPOLYSACCHARIDE - An isolated polysaccharide has the structure [-β(1,3)-D-GaIpNAc-β(1,4)-D-Glcp-] | 2013-10-03 |
20130261072 | OLIGOMER CONJUGATES OF HETEROPENTACYCLIC NUCLEOSIDES - The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer | 2013-10-03 |
20130261073 | MODULATOR OF ACTIVITY OF ADENYLATE CYCLASE - The present invention provides a novel compound capable of inhibiting cardiac adenylyl cyclase. | 2013-10-03 |
20130261074 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER - Described are methods and compositions for treating cancer that include a dopamine receptor (DR) antagonist such as thioridazine and a chemotherapeutic agent. Optionally, the chemotherapeutic agent is a DNA synthesis inhibitor such as cytarabine or a microtubule inhibitor such as paclitaxel or docetaxel. The methods and compositions are useful for the treatment of cancers such as acute myeloid leukemia. | 2013-10-03 |
20130261075 | COMBINATION - The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering 4-amino-1-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)pyrimidin-2(1H)-on 2′,2′-difluoro-2′-deoxycytidine, or a pharmaceutically acceptable salt thereof, and N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethy;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, to a human in need thereof. | 2013-10-03 |
20130261076 | ADMINISTRATION OF ERITORAN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT ORTHOMYXOVIRUS INFECTIONS - The present invention is directed to methods for treating orthomyxovirus infections comprising administering to a subject an effective amount of a compound of formula (I) | 2013-10-03 |
20130261077 | MANNOSE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS - The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: | 2013-10-03 |
20130261078 | Compositions of novel carbohydrate drug for treatment of human diseases - Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues. | 2013-10-03 |
20130261079 | HIGH MOLECULAR WEIGHT HEPAROSAN POLYMERS AND METHODS OF PRODUCTION AND USE THEREOF - High molecular weight heparosan polymers are described, as are methods of producing and using the high molecular weight heparosan polymers. | 2013-10-03 |
20130261080 | HYDROGEL TISSUE ADHESIVE FOR MEDICAL USE - A hydrogel tissue adhesive formed by reacting an aldehyde-functionalized polysaccharide containing pendant aldehyde groups with a water-dispersible, multi-arm amine is described. The hydrogel may be useful as a tissue adhesive or sealant for medical applications that require a more rapid degradation time, such as the prevention of undesired tissue-to tissue adhesions resulting from trauma or surgery. | 2013-10-03 |
20130261081 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE - A heterocyclic compound represented by the general formula (1) or a salt thereof: | 2013-10-03 |
20130261082 | Combination Therapy With Organic Arsenicals - The invention provides a combination therapy wherein one or more other therapeutic agents are administered with an organic arsenical, preferably SGLU-I or a pharmaceutically acceptable salt thereof. The invention also relates to methods for the treatment of cancer, comprising administering SGLU-I in combination with another therapeutic agent. Another aspect of the invention relates to a kit comprising SGLU-I and another therapeutic agent. | 2013-10-03 |
20130261083 | ADJUVANTS FOR INSECTICIDES - The invention relates to additives enhancing the activity of certain insecticides, to significantly increase the effect of such insecticides when applied to the exterior foliage of a plant, thus increasing the kill rate of feeding insects that are normally protected deep within other tissue structures of the plant. | 2013-10-03 |
20130261084 | METHOD OF IMPROVING RESPONSE TO CHEMOTHERAPY BY ADMINISTERING A PHOSPHOLIPID TOGETHER WITH CHEMOTHERAPEUTIC AGENTS, AND FORMULATIONS THEREFOR - Methods and formulations for improving efficacy of chemotherapeutic treatment. The formulation includes at least one chemotherapeutic agent and at least one phospholipid or a material comprising the same. The phospholipid facilitates entry of the at least one chemotherapeutic agent into cells of an afflicted individual. A sufficient dosage of a blood-thinning agent is optionally included to mitigate risk of developing blood clots attributable to administration of the chemotherapeutic agent(s). The chemotherapeutic agent(s) and the phospholipid(s), or the material containing the phospholipid(s), are administered in any order but in sufficient time proximity to one another such that the effect of the phospholipid(s) of facilitating entry of the chemotherapeutic agent(s) into the cells at least partially overlaps with the therapeutic effect of the chemotherapeutic agent(s). | 2013-10-03 |
20130261085 | METHOD OF IMPROVING RESPONSE TO CHEMOTHERAPY BY ADMINISTERING A PHOSPHOLIPID TOGETHER WITH CHEMOTHERAPEUTIC AGENTS, AND FORMULATIONS THEREFOR - Methods and formulations for improving efficacy of chemotherapeutic treatment. The formulation includes at least one chemotherapeutic agent and at least one phospholipid or a material comprising the same. The phospholipid facilitates entry of the at least one chemotherapeutic agent into cells of an afflicted individual. A sufficient dosage of a blood-thinning agent is optionally included to mitigate risk of developing blood clots attributable to administration of the chemotherapeutic agent(s). The chemotherapeutic agent(s) and the phospholipid(s), or the material containing the phospholipid(s), are administered in any order but in sufficient time proximity to one another such that the effect of the phospholipid(s) of facilitating entry of the chemotherapeutic agent(s) into the cells at least partially overlaps with the therapeutic effect of the chemotherapeutic agent(s). | 2013-10-03 |
20130261086 | MACROCYCLIC KINASE INHIBITORS - Compounds of Formula (I): wherein variables are defined herein, and pharmaceutically acceptable salts, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers for which FAK inhibition is beneficial. | 2013-10-03 |
20130261087 | SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENA VIRUSES - Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by hemorrhagic fever viruses is disclosed, i.e., including but not limited to, Arenaviridae (Junin, Machupo, Guanarito, Sabia, Lassa, Tacaribe, Pinchinde, and VSV), Filoviridae (ebola and Marburg viruses), Flaviviridae (yellow fever, omsk hemorrhagic fever and Kyasanur Forest disease viruses), and Bunyaviridae (Rift Valley fever). | 2013-10-03 |
20130261088 | NOVEL DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION - The present invention relates to novel derivatives of oxazaphosphorines that are pre-activated, to the methods for preparing same, to the pharmaceutical compositions containing same and to the therapeutic use thereof, in particular for treating cancer. | 2013-10-03 |
20130261089 | DIPHENYL SULFIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT WHICH CONTAINS SAME AS ACTIVE INGREDIENT - [Problem] To provide a diphenyl sulfide derivative which is useful as a pharmaceutical product that has excellent S1P3 antagonist activity. | 2013-10-03 |
20130261090 | METHOD FOR TREATMENT OF SORES IN THE ORAL CAVITY WITH A COMPOSITION CONTAINING ULTRAVIOLET LIGHT-ABSORBING INGREDIENTS - The invention provides a method for treating ulcerations of the oral cavity, such as canker sores, sores associated with hand, foot, and mouth disease (HFMD), and sores associated with herpangina, with compositions containing ultraviolet light-absorbing ingredients. The ultraviolet light-absorbing ingredients include avobenzone, homosalate, octisalate, octocrylene, and/or oxybenzone. These treatments accelerate the healing process of the ulcerations of the oral cavity. | 2013-10-03 |
20130261091 | Salicylic Acid Gel - A concentrated salicylic acid gel comprising salicylic acid and a stabilizer compound, wherein the salicylic acid comprises at least 30 wt % of the total weight of the gel. | 2013-10-03 |
20130261092 | METHOD OF SYNERGISTICALLY ENHANCING THE THERAPEUTIC EFFICACY AND SAFETY OF MEDICATION THROUGH A COMBINATION THERAPY - The present invention provides combinations, for treatment of subjects suffering from or at high risk of developing diseases and disorders involving expression of peroxisome proliferator-activated receptors (PPAR). The combinations include abscisic acid and one other bioactive agent, which together provide synergistic effects toward treatment or blocking of development of the disease or disorder. In exemplary embodiments, a combination of abscisic acid and a thiazolidinedione (TZD) is provided for increased insulin sensitivity and improved (i.e., reduced) obesity-induced inflammation. | 2013-10-03 |
20130261093 | COSMETIC COMPOSITION IN THE FORM OF AN OIL-IN-WATER EMULSION - A cosmetic composition in the form of an oil-in-water emulsion methods of using and producing cosmetic compositions is provided. The cosmetic composition includes an aqueous phase, an oil phase comprising a water-in-oil emulsifier, and an oil stabilizing component. The water-in-oil emulsifier is at concentration, by weight, of about 0.01% to about 6.0%, based upon weight of the composition. The oil stabilizing component includes one or both of an amphiphilic compound or a surfactant having an HLB of 13 or greater added to the aqueous phase. The oil stabilizing component is at a concentration, by weight, of about 0.01% to about 1.0%, based upon weight of the composition. The oil-in-water emulsion has an increased water load relative to water-in-oil emulsions without having an increased viscosity. | 2013-10-03 |
20130261094 | TUNABLE, BIODEGRADABLE LINKER MOLECULES FOR TRANSIENT CONJUGATION OF COMPONENTS IN DRUG DELIVERY SYSTEMS, AND DRUG DELIVERY SYSTEMS PREPARED THEREWITH - The present invention relates to a particular class of biodegradable linkers, ensuring transiently stable conjugation of building blocks and/or bioactive compounds into drug delivery systems (DDS), such as DDS based on polymeric micelles or hydrogels. In addition, the present invention relates to compounds, comprising said linkers, such compounds preferably being prodrugs. Further, the invention is directed to the use of said linkers, and especially said biodegradable linkers, in a drug delivery system. Moreover, the invention relates to controlled release system comprising a polymer matrix, capable of releasing an active ingredient, wherein the active ingredient is covalently linked to the polymer molecules of the polymer matrix through said linkers, as well as to a method of synthesising these linkers and preparing such controlled release systems. | 2013-10-03 |
20130261095 | Dexamethasone Formulations in a Biodegradable Material - Effective treatments of acute pain for extended periods of time are provided. Through the administration of an effective amount of dexamethasone at or near a target site, one can relieve pain cause by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least twenty-five days. In some embodiments, the relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 2013-10-03 |
20130261096 | Formulation For Hormonotherapy - The present invention relates to a formulation as a nanoemulsion, comprising a continuous aqueous phase and at least one dispersed phase, and comprising:
| 2013-10-03 |
20130261097 | PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING HYPOGONADISM - A pharmaceutical composition useful for treating hypogonadism is disclosed. The composition comprises an androgenic or anabolic steroid, a C1-C4 alcohol, a penetration enhancer such as isopropyl myristate, and water. Also disclosed is a method for treating hypogonadism utilizing the composition. | 2013-10-03 |
20130261098 | ORGANIC ELECTROLUMINESCENT DEVICE - The present invention relates to compounds of the general formula (S-A)n-T, in which at least one fluorescent group S is linked to a phosphorescent group T via a divalent group A, to the use thereof in an electronic device, and to a formula to a formulation and an electronic device which comprise the novel compounds. | 2013-10-03 |
20130261099 | Fatty Acid Inhibitors - Fatty acid inhibitors, pharmaceutical compositions including fatty acid inhibitors, methods for using fatty acid inhibitors to treat a variety of diseases, and methods for preparing fatty acid inhibitors are provided herein. | 2013-10-03 |
20130261100 | PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS - The invention relates pyridine amide derivative of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R | 2013-10-03 |
20130261101 | BICYCLIC AZAHETEROCYCLOBENZYLAMINES AS PI3K INHIBITORS - The present invention provides bicyclic azaheterocyclobenzylamines of Formula I: | 2013-10-03 |
20130261102 | HETEROCYCLIC COMPOUNDS AND USES THEREOF - Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein. | 2013-10-03 |
20130261103 | PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF - Pyridazinone compounds of Formula I including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. | 2013-10-03 |
20130261104 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER - Methods of use of compounds of formula (I) for treating cancer: | 2013-10-03 |
20130261105 | NOVEL PYRAZOLOPYRIMIDINES - This invention relates to novel pyrazolopyrimidines and their use as metabotropic glutamate 5 receptor antagonists (mGlu5 receptor antagonists), pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of mGlu5 receptor mediated disorders. | 2013-10-03 |
20130261106 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF - The present invention relates to compounds of formula (I): | 2013-10-03 |
20130261107 | BICYCLIC OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE AS ALLOSTERIC MODULATORS OF MGLUR5 RECEPTORS - In one aspect, the invention relates to novel bicyclic oxazole and thiazole compounds which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (“mGluR5”); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions; and methods for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2013-10-03 |
20130261108 | COMPOSITIONS AND METHODS FOR MODULATING FARNESOID X RECEPTORS - The present invention relates to compounds of Formula (I), a stereoisomer, enantiomer, a pharmaceutically acceptable salt or an amino acid conjugate thereof; wherein variables are as defined herein; and their pharmaceutical compositions, which are useful as modulators of the activity of Farnesiod X receptors (FXR). | 2013-10-03 |
20130261109 | ANTITUMOR AGENT - The invention provides a method of inhibiting binding between acetylated histone and a bromodomain-containing protein in a mammal, as well as a method of shrinking or killing of cancer cells expressing a bromodomain-containing protein or inhibiting the growth of cancer cells expressing a bromodomain-containing protein in a mammal. The methods involve administering an effective amount of (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide or a dihydrate thereof to the mammal. | 2013-10-03 |
20130261110 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES - The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides novel 1,4-benzodiazepine-2,5-dione compounds, and methods of using novel 1,4-benzodiazepine-2,5-dione compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, and the like. | 2013-10-03 |
20130261111 | TETRAHYDROPYRROLOTHIAZINE COMPOUNDS - The present invention provides compounds of Formula I: | 2013-10-03 |
20130261112 | Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators - Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure: | 2013-10-03 |
20130261113 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS - This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients. | 2013-10-03 |
20130261114 | COMPOUNDS USEFUL AS INHIBITORS OF CHOLINE KINASE - The present invention relates to compounds useful as inhibitors of choline kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | 2013-10-03 |
20130261115 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE - The invention relates to substituted imidazo-, pyrazolopyrazines and imidazotriazines and processes for their preparation, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, in particular of hematological disorders, preferably of leukopenias and neutropenias. | 2013-10-03 |
20130261116 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN KINASES - The present invention provides, inter alia, compounds of formula I as protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them. | 2013-10-03 |
20130261117 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR - Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. | 2013-10-03 |
20130261118 | COMPOUNDS FOR ALZHEIMER'S DISEASE - The present disclosure relates to novel indole and tetrahydroindole core compounds useful for the treatment of disorders associated with a defect in vesicular transport (e.g., axonal transport). | 2013-10-03 |
20130261119 | Novel Anti-Cancer Agents - The present invention provides a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or pro-drug thereof. Further provided is a method of treatment of cancer in a subject comprising administering to said subject an effective amount of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is the use of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof in the preparation of a medicament for the treatment of cancer. In addition, the present invention also provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. | 2013-10-03 |
20130261120 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS - The present invention relates to:
| 2013-10-03 |
20130261121 | Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disubstituted-hepta-1,6-diene-3,5-d- ione structural scaffold, their biological activity, and uses thereof - The present invention includes compounds, pharmaceuticals and cosmetics having at least one (substituted phenyl)-propenal moiety. The compounds and compositions of the present invention are useful in the treatment or prevention of medical conditions including androgen associated conditions, androgen associated inflammation, a wound (the compounds assist with wound healing), acne, rheumatoid arthritis, psoriasis, rosacea, and alopecia; Kennedy's disease (spinal and bulbar muscular atrophy, or SBMA), polyglutamine-mediated motor neuron degeneration; cancers such as prostate cancer, bladder cancer, breast cancer, ovarian cancer, hepatocellular (liver) cancer, and pancreatic cancer; and other medical conditions described herein. Treatment of such medical conditions includes administering to an individual suffering from a medical condition describe herein, a therapeutically effective amount of any of the disclosed compounds, their derivatives, or pharmaceutical compositions thereof. | 2013-10-03 |
20130261122 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors - The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same. | 2013-10-03 |
20130261123 | Novel Substituted Bicyclic Aromatic Compounds as S-Nitrosoglutathione Reductase Inhibitors - The present invention is directed to novel substituted bicyclic aromatic compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same. | 2013-10-03 |
20130261124 | THERAPEUTIC METHODS AND AGENTS FOR TREATING MYOTONIC DYSTROPHY - The invention provides compounds, compositions and methods for treating myotonic dystrophy. The compounds can selectively bind to CUG repeats in RNA, or to CTG repeats in DNA, and inhibit replication of the nucleic acids. | 2013-10-03 |
20130261125 | INDAZOLE DERIVATIVES USEFUL AS ERK INHIBITORS - The present invention provides a compound of the Formula I, or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R | 2013-10-03 |
20130261126 | BRIMONIDIINE GEL COMPOSITIONS AND METHODS OF USE - Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage. | 2013-10-03 |
20130261127 | COMPOSITION FOR ENHANCING ATHLETIC PERFORMANCE - A composition can include a plurality of active ingredients such as pyruvate, niacin, riboflavin, lipoic acid, and amidated glycine. The concentration by weight of the first active ingredient (pyruvate) in the composition can be greater than the concentration by weight of each one of the other active ingredients. The composition can affect ATP and Krebs efficiency when ingested by an animal. | 2013-10-03 |
20130261128 | CONTINUOUS ARYCYCLIC COMPOUND - This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof. | 2013-10-03 |
20130261129 | CHEMOKINE RECEPTOR ANTAGONISTS - Disclosed herein are chemokine receptor antagonists of formula (I) | 2013-10-03 |
20130261130 | NEUROTRYPSIN INHIBITORS - The invention relates to acylamino-phthalic acid amides and related compounds of formula (I) wherein A is —CON—R | 2013-10-03 |
20130261131 | PHARMACEUTICAL COMPOSITIONS AND MENTODS FOR TREATMENT OF FUNGAL INFECTIONS - Pharmaceutical compositions and methods for treating skin or mucus fungal infections of feet, nails, groin, hands, tongue and other locations are disclosed herein. The pharmaceutical composition disclosed herein comprises at least one triazole agent. Methods of treating tinea pedis, tinea manuum, tinea unguium, tinea cruris, tinea corpora, tinea versicolor, candidiasis, aspergillosis, onychomycosis, coccidiodomycosis, cryptococcal meningitis, histoplasmosis, hoof thrush, hoof rot, tongue and mouth lesions, seborrheic dermatitis, and combinations thereof, are also presently disclosed. | 2013-10-03 |
20130261132 | CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS - Compounds of general formula (I), their use as calcium receptor-active compounds for the prophylaxis, treatment or amelioration of physiological disorders or diseases associated with disturbances of CaSR activity, such as hyperparathyroidism, pharmaceutical compositions comprising said compounds, and methods of treating diseases with said compounds. | 2013-10-03 |
20130261133 | Therapeutic Compounds for Protozoal and Microbial Infections and Cancer - The compounds of the invention exhibit antiprotozoal, antimicrobial, and anticancer properties that are useful for the treatment or prevention of infections or cancer in a patient (e.g., a human). For example, the compounds and methods described herein can be used for the treatment or prevention of protozoal infections such as leishmaniasis, malaria, and | 2013-10-03 |
20130261134 | MESYLATE SALT FORMS OF A POTENT HCV INHIBITOR - This invention relates to novel mesylate salt forms of the following Compound (1), and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in methods for the treatment of Hepatitis C Viral (HCV) infection: | 2013-10-03 |
20130261135 | METALLOENZYME INHIBITOR COMPOUNDS - The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes. | 2013-10-03 |
20130261136 | COFFEE EXTRACTS AS INGREDIENTS OF FOODS, DRUGS, COSMETICS, DIETARY SUPPLEMENTS, AND BIOLOGICS - Embodiments are related to compositions of matter comprising a food, drug, cosmetic, dietary supplement, or biologic product, said product comprised of a phytochemical fraction recovered from a crude caffeine, said phytochemical fraction having a ratio of polyphenols to caffeine of about 20, 10-30 or 40, or greater than 10. In related embodiments, said phytochemical fraction is a retentate of a filtration process of a water suspension of crude caffeine, and wherein said crude caffeine is a product of a green coffee bean decaffeination process. In other related embodiments, said compositions of matter are useful for facilitating neuroprotection, inhibiting COX-2 or stimulating glucose uptake. | 2013-10-03 |
20130261137 | Methods, Compounds and Compositions Relating to Activating a Latent Virus - The present invention relates to, inter alia, an anti-microtubule agent for use in a method of treating a subject having a latent virus, the method comprising: administering the anti-microtubule agent and an anti-viral agent to the subject. | 2013-10-03 |
20130261138 | FUSED HETEROCYCLIC INDANE CARBOXAMIDE CGRP RECEPTOR ANTAGONISTS - The present invention is directed to fused heterocyclic indane carboxamide derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved. | 2013-10-03 |
20130261139 | USE OF A QUINAZOLINE COMPOUND IN PREPARING A MEDICAMENT AGAINST FLAVIVIRIDAE VIRUS - Disclosed is a use of a quinazoline compound of Formula I having 2,4-diaminoquinazoline as a parent nucleus in preparation of a medicament for treating diseases caused by flaviviridae infection, especially a use in combating Hepatitis C virus infection and Dengue fever virus infection. | 2013-10-03 |
20130261140 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS - The present invention is directed to novel tricyclic heterocycles of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. I | 2013-10-03 |
20130261141 | NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES - The present application relates to novel heterocyclic compounds, to processes for preparation thereof and to the use thereof for controlling animal pests, which also include arthropods and especially insects. | 2013-10-03 |
20130261142 | COMPOUNDS USED FOR TREATING CANCER AND THE USE THEREOF - The present invention discloses compounds for the treatment of cancer and its application. These compounds comprises one of the following compound: Ammonium pyrrolidinedithiocarbamate | 2013-10-03 |
20130261143 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2013-10-03 |
20130261144 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2013-10-03 |
20130261145 | PHARMACEUTICAL FORMULATION CONTAINING GELLING AGENT - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2013-10-03 |
20130261146 | NITRIC OXIDE AND ITS BIOMEDICAL SIGNIFICANCE - A pharmaceutical composition for stimulating nitric oxide production in mammalian cells, the pharmaceutical composition including at least one compound selected from a group consisting of: 2,3-dihydroxypropyl oleate; bis(m-phenoxyphenyl) ether; 6-acetyl-5,6,6a,7-tetrahydro-4H-dibezo(de,g)quinoline; and (+)-N-(p-(2-methylbutoxy)benzylidene)-4-(2-methylbutyl)aniline. | 2013-10-03 |
20130261147 | COMPOSITION FOR PREVENTING OR TREATING DEMENTIA - There is provided use of | 2013-10-03 |
20130261148 | PROTECTED ANTIMICROBIAL COMPOUNDS FOR HIGH TEMPERATURE APPLICATIONS - Provided are protected antimicrobial compounds which are useful for controlling microorganisms in aqueous or water-containing systems, such as oil or gas field fluids, at elevated temperature. The antimicrobial compounds are of the formula I: | 2013-10-03 |
20130261149 | LIQUID PHARMACEUTICAL FORMULATIONS OF PALONOSETRON - The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments. | 2013-10-03 |
20130261150 | LIQUID PHARMACEUTICAL FORMULATIONS OF PALONOSETRON - The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments. | 2013-10-03 |
20130261151 | AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS - A compound satisfying formula I, a prodrug, N-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof; | 2013-10-03 |
20130261152 | ORALLY EFFECTIVE METHYLPHENIDATE EXTENDED RELEASE POWDER AND AQUEOUS SUSPENSION PRODUCT - An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50%, or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 to about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile. | 2013-10-03 |
20130261153 | USE OF CCR3-INHIBITORS - The present invention relates to CCR3 inhibitors of formula 1, | 2013-10-03 |
20130261154 | FUNGICIDAL AZOCYCLIC AMIDES - Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof, | 2013-10-03 |
20130261155 | 1-(HETEROCYCLIC CARBONYL) PIPERIDINES - The present invention relates to fungicidal 1-(heterocyclic carbonyl) piperidines and their thiocarbonyl derivatives, their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions. | 2013-10-03 |
20130261156 | PHARMACEUTICAL COMPOSITION - The present invention provides a pharmaceutical composition or a solid preparation containing a stabilized pharmaceutically active ingredient and a stabilizing method thereof. | 2013-10-03 |
20130261157 | Novel multicomponent crystals made ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester and 2-[2-[(2,6-dichlorphenyl)-amino]-phenyl]-acetic acid - The invention relates to novel multicomponent crystals, to the production thereof, and to the use thereof for treating pain conditions, in particular of unclear genesis, by means of a simultaneous effect on pains which are caused by muscle tension or degenerative joint diseases as well as on pains that are based on inflammatory processes. The novel multicomponent crystals contain ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester (flupirtine) and 2-[2-[(2,6-dichlorphenyl)-amino]-phenyl]-acetic acid (diclofenac) as the sole active ingredient combination and can be produced by dissolving the two components in a molar ratio of 1.0:0.9 to 1.0:1.1 in an inert organic solvent and subsequently crystallizing the complex compound. | 2013-10-03 |
20130261158 | FUNGICIDAL N-(2-PHENOXYETHYL)CARBOXAMIDE DERIVATIVES AND THEIR AZA, THIA AND SILA ANALOGUES - The present invention relates to fungicide N-(2-phenoxyethyl)carboxamide derivatives of formula (I), their aza, thia and sila analogues, their process of preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions. Formula (1) wherein A, T, W, X, n and Z | 2013-10-03 |
20130261159 | OXAZOLYL-METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS - The invention relates to oxazolyl-methylether derivatives of formula (I), | 2013-10-03 |
20130261160 | METHOD OF PREPARATION OF METAXALONE - The present invention relates to a method of preparation of metaxalone comprising reaction of triglycidyl isocyanurate (TGIC) with m-xylenol, characterized in that said reaction is carried out in a solvent mixture comprising an aprotic polar solvent with dielectric constant greater than or equal to 30 and at least one other solvent selected from the group comprising apolar solvents and aprotic polar solvents with dielectric constant below 30 said solvent mixture comprising from 5 to 40 wt. % of said first solvent and from 95 to 60 wt. % of said second solvent, adding the TGIC at a temperature between 30° C. and 50° C., and after adding the TGIC, raising the temperature of the reaction solution to a value between 80° C. and 180° C. in a time between 120 and 180 minutes at a rate of increase not greater that 1.25° C. per minute. The invention also relates to a metaxalone with a reduced content of impurities derived from incomplete reactions and/or side reactions of the method of production. | 2013-10-03 |
20130261161 | ANTIPARASITIC FORMULATIONS - Fipronil co-formulations are provided herein. The formulations comprise an organic solvent, an alcohol co-solvent, and one or more antioxidants. The formulations provided herein are antiparasitic, and can be used, for example, to combat dog and cat parasites, such as, fleas and ticks. | 2013-10-03 |
20130261162 | PARASITICIDAL FORMULATION - The present invention provides a parasiticidal formulation comprising: Fipronil, or a veterinarily acceptable derivative thereof; at least one C | 2013-10-03 |
20130261163 | ACTIVE COMPOUND COMBINATIONS HAVING INSECTICIDAL AND ACARICIDALPROPERTIES - The invention relates to novel active compound combinations having very good insecticidal and acaricidal properties and containing
| 2013-10-03 |
20130261164 | PYRROLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY - The present invention relates to substituted pyrrole compounds and compositions comprising substituted pyrrole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted pyrrole compound of the invention, or a pharmaceutical composition comprising such a compound. | 2013-10-03 |
20130261165 | PREVENTION AND TREATMENT OF DISEASES CHARACTERIZED BY MESENCEPHALIC DOPAMINERGIC NEURON CELL DEATH - Provided herein are methods for the prevention and treatment of diseases affecting mesencephalic dopaminergic neurons including, for example, Parkinson's disease. Suitable therapeutic agents for use in the methods described herein include, for example, agents that upregulate the expression En-1 and/or FoxA2 in target cells. | 2013-10-03 |
20130261166 | METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE - This invention relates to methods and compositions for treating neurological disease, and more particularly to methods of delivering iRNA agents to neural cells for the treatment of neurological diseases. | 2013-10-03 |
20130261167 | ANCCA as a Diagnostic Biomarker and Therapeutic Target for Breast Cancers - The present invention provides methods of diagnosing breast cancer, confirming a diagnosis of breast cancer, predicting the survival of a breast cancer patient, and providing a therapeutic target of treatment in a breast cancer patient by measuring relatively increased expression levels of ANCCA. Expression levels of ANCCA can be measured be determining the levels mRNA or protein. The expression levels can be compared to a predetermined threshold level or to a control, e.g., a positive or negative control. | 2013-10-03 |
20130261168 | NUCLEIC ACID COMPLEXES - The invention relates to nucleic acid complexes, methods of preparation thereof, and uses thereof for delivering a nucleic acid into a cell. | 2013-10-03 |
20130261169 | Micro-RNA Family That Modulates Fibrosis and Uses Thereof - The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease. | 2013-10-03 |
20130261170 | BACTERIALLY DERIVED INTACT MINICELLS THAT ENCOMPASS PLASMID FREE FUNCTIONAL NUCLEIC ACID FOR IN VIVO DELIVERY TO MAMMALIAN CELLS - Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation. | 2013-10-03 |